Adenovirus Vector Standards Should Be Loosened For Healthier Patients
Executive Summary
FDA should loosen the standard for levels of replication-competent adenovirus in gene therapy products for all but the most severely immunocompromised patients, the Biological Response Modifiers Advisory Committee suggested July 13.